156 related articles for article (PubMed ID: 17266043)
41. Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.
Gatti L; Cossa G; Tinelli S; Carenini N; Arrighetti N; Pennati M; Cominetti D; De Cesare M; Zunino F; Zaffaroni N; Perego P
J Pharmacol Exp Ther; 2014 Mar; 348(3):360-71. PubMed ID: 24345465
[TBL] [Abstract][Full Text] [Related]
42. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
[TBL] [Abstract][Full Text] [Related]
43. In vitro inhibition of AKR1Cs by sulphonylureas and the structural basis.
Zhao Y; Zheng X; Zhang H; Zhai J; Zhang L; Li C; Zeng K; Chen Y; Li Q; Hu X
Chem Biol Interact; 2015 Oct; 240():310-5. PubMed ID: 26362498
[TBL] [Abstract][Full Text] [Related]
44. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.
Wsol V; Szotakova B; Martin HJ; Maser E
Toxicology; 2007 Sep; 238(2-3):111-8. PubMed ID: 17618725
[TBL] [Abstract][Full Text] [Related]
45. Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism.
Ji Q; Chang L; VanDenBerg D; Stanczyk FZ; Stolz A
Prostate; 2003 Mar; 54(4):275-89. PubMed ID: 12539226
[TBL] [Abstract][Full Text] [Related]
46. Induction of neoplastic transformation by ectopic expression of human aldo-keto reductase 1C isoforms in NIH3T3 cells.
Chien CW; Ho IC; Lee TC
Carcinogenesis; 2009 Oct; 30(10):1813-20. PubMed ID: 19696165
[TBL] [Abstract][Full Text] [Related]
47. Expression of human aldo-keto reductase 1C2 in cell lines of peritoneal endometriosis: potential implications in metabolism of progesterone and dydrogesterone and inhibition by progestins.
Beranič N; Brožič P; Brus B; Sosič I; Gobec S; Lanišnik Rižner T
J Steroid Biochem Mol Biol; 2012 May; 130(1-2):16-25. PubMed ID: 22245609
[TBL] [Abstract][Full Text] [Related]
48. Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas.
Gallego MA; Joseph B; Hemström TH; Tamiji S; Mortier L; Kroemer G; Formstecher P; Zhivotovsky B; Marchetti P
Oncogene; 2004 Aug; 23(37):6282-91. PubMed ID: 15286713
[TBL] [Abstract][Full Text] [Related]
49. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.
Tang X; Wu W; Sun SY; Wistuba II; Hong WK; Mao L
Mol Cancer Res; 2004 Dec; 2(12):685-91. PubMed ID: 15634757
[TBL] [Abstract][Full Text] [Related]
50. DNA methylation of DKK3 modulates docetaxel chemoresistance in human nonsmall cell lung cancer cell.
Tao L; Huang G; Chen Y; Chen L
Cancer Biother Radiopharm; 2015 Mar; 30(2):100-6. PubMed ID: 25760729
[TBL] [Abstract][Full Text] [Related]
51. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
52. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
53. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
54. SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.
Shin DH; Choi YJ; Park JW
Cancer Res; 2014 Jan; 74(1):298-308. PubMed ID: 24240701
[TBL] [Abstract][Full Text] [Related]
55. Transcriptomic Profiling Reveals AKR1C1 and AKR1C3 Mediate Cisplatin Resistance in Signet Ring Cell Gastric Carcinoma via Autophagic Cell Death.
Phoo NLL; Dejkriengkraikul P; Khaw-On P; Yodkeeree S
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830394
[TBL] [Abstract][Full Text] [Related]
56. miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
Bar J; Gorn-Hondermann I; Moretto P; Perkins TJ; Niknejad N; Stewart DJ; Goss GD; Dimitroulakos J
Clin Lung Cancer; 2015 Nov; 16(6):e121-9. PubMed ID: 25703099
[TBL] [Abstract][Full Text] [Related]
57. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
Beranič N; Gobec S; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
[TBL] [Abstract][Full Text] [Related]
58. Resistance to platinum-based chemotherapy in lung cancer cell lines.
Chen J; Emara N; Solomides C; Parekh H; Simpkins H
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1103-11. PubMed ID: 20953859
[TBL] [Abstract][Full Text] [Related]
59. Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer.
d'Amato TA; Landreneau RJ; McKenna RJ; Santos RS; Parker RJ
Ann Thorac Surg; 2006 Feb; 81(2):440-6; discussion 446-7. PubMed ID: 16427828
[TBL] [Abstract][Full Text] [Related]
60. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.
Rizner TL; Lin HK; Peehl DM; Steckelbroeck S; Bauman DR; Penning TM
Endocrinology; 2003 Jul; 144(7):2922-32. PubMed ID: 12810547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
